Biofrontera Says Last Patient Completes 1-Year Follow-Up in Skin Cancer Treatment Study; Shares Jump

MT Newswires Live
09 Jan

Biofrontera (BFRI) said Wednesday that the last patient completed the one-year follow-up visit in a phase 3 study of the use of Ameluz and RhodoLED photodynamic therapy to treat superficial basal cell carcinoma, a type of skin cancer.

The study evaluated safety and efficacy in 187 patients with at least one clinically and histologically confirmed superficial basal cell carcinomas.

The company said data from the follow-up will be included in its supplemental new drug application submission to the US Food and Drug Administration, expected in Q3.

Biofrontera shares were up nearly 12% in recent trading.

Price: 1.24, Change: +0.13, Percent Change: +11.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10